Status:
TERMINATED
MisOpRostol Effect on Second Trimester Abortion Blood Loss
Lead Sponsor:
Stanford University
Conditions:
Blood Loss, Surgical
Second Trimester Abortion
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Although serious complications from second trimester abortion are rare hemorrhage is the most common cause of procedural abortion related morbidity and mortality. Misoprostol is a prostaglandin E1 ana...
Eligibility Criteria
Inclusion
- Pregnant people, 18 years of age or older; intrauterine pregnancy between 18/0-23/6 weeks of gestational age (by ultrasound dating performed prior to same day of enrollment visit) consented for an induced abortion; English or Spanish speaking, able to consent for a research study, literate in English or Spanish.
Exclusion
- known coagulopathy, suspected morbidly adherent placenta spectrum, multiple gestation, current infection, ruptured membranes, or fetal demise at time of enrollment.
Key Trial Info
Start Date :
February 8 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 12 2024
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT06078501
Start Date
February 8 2024
End Date
July 12 2024
Last Update
August 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University Hospital
Palo Alto, California, United States, 94304